These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 8092833)

  • 1. Comparative prophylactic efficacies of ciprofloxacin, ofloxacin, cefazolin, and vancomycin in experimental model of staphylococcal wound infection.
    Kernodle DS; Kaiser AB
    Antimicrob Agents Chemother; 1994 Jun; 38(6):1325-30. PubMed ID: 8092833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative prophylactic efficacy of cefazolin and vancomycin in a guinea pig model of Staphylococcus aureus wound infection.
    Kernodle DS; Kaiser AB
    J Infect Dis; 1993 Jul; 168(1):152-7. PubMed ID: 8515103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of prophylaxis with beta-lactams and beta-lactam-beta-lactamase inhibitor combinations against wound infection by methicillin-resistant and borderline-susceptible Staphylococcus aureus in a guinea pig model.
    Kernodle DS; Kaiser AB
    Antimicrob Agents Chemother; 1993 Apr; 37(4):702-7. PubMed ID: 8494364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Levofloxacin versus ciprofloxacin, flucloxacillin, or vancomycin for treatment of experimental endocarditis due to methicillin-susceptible or -resistant Staphylococcus aureus.
    Entenza JM; Vouillamoz J; Glauser MP; Moreillon P
    Antimicrob Agents Chemother; 1997 Aug; 41(8):1662-7. PubMed ID: 9257737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of sparfloxacin, temafloxacin, and ciprofloxacin for prophylaxis and treatment of experimental foreign-body infection by methicillin-resistant Staphylococcus aureus.
    Cagni A; Chuard C; Vaudaux PE; Schrenzel J; Lew DP
    Antimicrob Agents Chemother; 1995 Aug; 39(8):1655-60. PubMed ID: 7486895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of topical taurolidine versus ciprofloxacin, ofloxacin, and fortified cefazolin in a rabbit Staphylococcus aureus keratitis model.
    Oguz H; Ozbilge H; Oguz E; Gurkan T
    Curr Eye Res; 2005 Mar; 30(3):155-61. PubMed ID: 15804740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of garenoxacin in treatment of experimental endocarditis due to Staphylococcus aureus or viridans group streptococci.
    Entenza JM; Vouillamoz J; Glauser MP; Moreillon P
    Antimicrob Agents Chemother; 2004 Jan; 48(1):86-92. PubMed ID: 14693523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of levofloxacin, alatrofloxacin, and vancomycin for prophylaxis and treatment of experimental foreign-body-associated infection by methicillin-resistant Staphylococcus aureus.
    Vaudaux P; Francois P; Bisognano C; Schrenzel J; Lew DP
    Antimicrob Agents Chemother; 2002 May; 46(5):1503-9. PubMed ID: 11959588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nationwide Organism Susceptibility Patterns to Common Preoperative Prophylactic Antibiotics: What Are We Covering?
    Nodzo SR; Boyle KK; Frisch NB
    J Arthroplasty; 2019 Jul; 34(7S):S302-S306. PubMed ID: 30745218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Temporin A as a prophylactic agent against methicillin sodium-susceptible and methicillin sodium-resistant Staphylococcus epidermidis vascular graft infection.
    Ghiselli R; Giacometti A; Cirioni O; Mocchegiani F; Orlando F; Kamysz W; Del Prete MS; Lukasiak J; Scalise G; Saba V
    J Vasc Surg; 2002 Nov; 36(5):1027-30. PubMed ID: 12422090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of cefazolin, cefamandole, vancomycin, and LY146032 for prophylaxis of experimental Staphylococcus epidermidis endocarditis.
    Wheat LJ; Smith JW; Reynolds J; Bemis AT; Treger T; Norton JA
    Antimicrob Agents Chemother; 1988 Jan; 32(1):63-7. PubMed ID: 2831815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative study of cefazolin, cefamandole, and vancomycin for surgical prophylaxis in cardiac and vascular operations. A double-blind randomized trial.
    Maki DG; Bohn MJ; Stolz SM; Kroncke GM; Acher CW; Myerowitz PD
    J Thorac Cardiovasc Surg; 1992 Nov; 104(5):1423-34. PubMed ID: 1434726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacies of moxifloxacin, ciprofloxacin, and vancomycin against experimental endocarditis due to methicillin-resistant Staphylococcus aureus expressing various degrees of ciprofloxacin resistance.
    Entenza JM; Que YA; Vouillamoz J; Glauser MP; Moreillon P
    Antimicrob Agents Chemother; 2001 Nov; 45(11):3076-83. PubMed ID: 11600359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity of temafloxacin against respiratory pathogens.
    Swanson RN; Hardy DJ; Chu DT; Shipkowitz NL; Clement JJ
    Antimicrob Agents Chemother; 1991 Mar; 35(3):423-9. PubMed ID: 2039192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo efficacies of levofloxacin and ciprofloxacin in acute murine hematogenous pyelonephritis induced by methicillin-susceptible and-resistant Staphylococcus aureus strains.
    Frosco MB; Melton JL; Stewart FP; Kulwich BA; Licata L; Barrett JF
    Antimicrob Agents Chemother; 1996 Nov; 40(11):2529-34. PubMed ID: 8913458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antistaphylococcal activity of DX-619, a new des-F(6)-quinolone, compared to those of other agents.
    Bogdanovich T; Esel D; Kelly LM; Bozdogan B; Credito K; Lin G; Smith K; Ednie LM; Hoellman DB; Appelbaum PC
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3325-33. PubMed ID: 16048943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vancomycin versus cefazolin prophylaxis for cerebrospinal shunt placement in a hospital with a high prevalence of meticillin-resistant Staphylococcus aureus.
    Tacconelli E; Cataldo MA; Albanese A; Tumbarello M; Arduini E; Spanu T; Fadda G; Anile C; Maira G; Federico G; Cauda R
    J Hosp Infect; 2008 Aug; 69(4):337-44. PubMed ID: 18602187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differing activities of quinolones against ciprofloxacin-susceptible and ciprofloxacin-resistant, methicillin-resistant Staphylococcus aureus.
    Maple PA; Hamilton-Miller JM; Brumfitt W
    Antimicrob Agents Chemother; 1991 Feb; 35(2):345-50. PubMed ID: 1827242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In-vitro activity of three fluoroquinolones, cefotaxime and clindamycin against staphylococci.
    Schumacher-Perdreau F; Peters G
    Zentralbl Bakteriol; 1995 Oct; 282(4):389-93. PubMed ID: 9810661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Topical antibiotic therapy for the treatment of experimental Staphylococcus aureus keratitis.
    Callegan MC; Hobden JA; Hill JM; Insler MS; O'Callaghan RJ
    Invest Ophthalmol Vis Sci; 1992 Oct; 33(11):3017-23. PubMed ID: 1399405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.